Rhumbline Advisers Achilles Therapeutics PLC Put Options Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding ACHL
# of Institutions
8Shares Held
4.05MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN3.8MShares$5.63 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA192KShares$283,9060.0% of portfolio
-
Xtx Topco LTD London, X038.9KShares$57,6060.0% of portfolio
-
Brave Asset Management Inc10KShares$14,8000.0% of portfolio
-
Endurance Wealth Management, Inc.2KShares$2,9600.0% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $60.3M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...